Corporate Presentation



Hanmi Pharmaceutical Co., Ltd.

Forward-Looking Statements




This presentation contains forward-looking statements with respect to future financial condition, results of operations and businesses of Hanmi Pharmaceutical Company. By their nature, forward-looking statements and forecasts involve risk and uncertainties because they relate to events and circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed in or implied by the forward-looking information and statements. These risks and uncertainties include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities. Hanmi does not undertake any obligation to update or revise any forward-looking information or statements.

Our Businesses



Strong Strategic Alliances around the Globe



Major R&D Achievements



History of Global Collaborations with partners

"The Way to Sustain Innovation and Growth"



Amosartan Amlodipine+Losartan



Eflapegrastim



Long acting GCSF analog



Hvaluronate



Efpeglenatide Weekly GLP-1



Belvarafenib RAF inhibitor



Rosuzet Rosuvastatin +Ezetimibe



Immuno-Oncoloav

2009

2012

2014

2016

2018

2011



Orascovery **Platform Tech** Oral Paclitaxel / Irinotecan 2013



Royelito Irbesartan+Atorvastatin 2015



Poziotinib Pan-HER inhibitor 2017



Anti-PD-1/HER2 Bi-specific antibody Targeted Immuno-Oncology

2019



New Antibody Sequence Immuno-Oncology

Rare Disease



The True Innovation should

Embrace patients with rare disease

Rare Disease Programs in Clinical Stage

Congenital Hyper	_
insulinism (CHI)	

Weekly Glucagon
Orphan Drug Designation
in US & EU

Short Bowel
Syndrome (SBS)

Monthly GLP-2
Orphan Drug Designation
in US & EU

Acute Myeloid Leukemia (AML)

FLT3 inhibitor
Orphan Drug Designation
in US

Fabry & Maroteaux-Lamy syndrome

Monthly enzyme Replacement Therapy

Innovative R&D Pipeline (Jan 2020)



	Pre-Clinical	Phase 1	Phase 2	Phase 3	Registration
8 Obesity/NASH Diabetes	HM14320 (LAPSGlucagon Combo) Obesity/NASH/Diabetes	HM15211 (LAPSTriple Agonist) NASH	HM12525A (LAPSGLP/GCG) Obesity	Efpeglenatide (LAPSExd4 Analog) Diabetes SANOFI	
	HM14220 (LAPSInsulin Combo) Diabetes SANOFI	HM15136 (LAPSGlucagon Analog) Obesity			
	HM12480 (^{LAPS} Insulin148) Diabetes	HM12460A, HM12470 (LAPS Insulin) - Diabetes			
13 Oncology	Undisclosed BsAb Sequence Targeted immuno-oncology **Phanes**	Belvarafenib (Pan-RAF Inhibitor) Solid tumor Genentech	Poziotinib (Pan-HER Inhibitor) NSCLC & Breast cancer SPECTRUM	Oraxol (Oral Paclitaxel + Encequidar) Metastatic Breast cancer	Rolontis® (Eflapegrastim) Neutropenia
	HM97594 (EZH1/2 Dual Inhibitor) Hematol. malignancies	HM43239 (FLT3 Inhibitor) AML	Oratecan (Oral Irinotecan + Encequidar) Solid tumor		
	HM87171 (ADOR Antagonist) Cancer Immunotherapy	IBI315/BH2950 (PD-1/HER2 BsAb) Targeted immuno-oncology	Oradoxel (Oral Docetaxel + Encequidar) Solid tumor		
	HM97346 (LSD1 Inhibitor) Solid tumors/Hematol. malignancies	FLX475 (CCR4 inhibitor) Solid tumor			
4 Rare Diseases 3 Others	HM15450 (LAPSASB) Mucopolysaccharidosis	HM15136 (LAPSGlucagon Analog) Congenital hyperinsulinism	Efpegsomatropin (^{LAPS} hGH) GH deficiency		
		HM15912 (LAPSGLP-2 Analog) Short bowel syndrome	Luminate® (Integrin inhibitor) Diabetic Macular Edema		
		Luminate® (Integrin inhibitor) Retinitis Pigmentosa	HM71224 (BTK Inhibitor) Autoimmune/Allergic diseases		

Thank you

Hanmi Pharmaceutical Co., Ltd.